Erasca closed at $14.91 on Nov 4, up 1.84%, 33.6% below its 52-week closing high. Volume of 3.5M shares was 0.71× its 20-day average (below normal).
Split-adjusted performance: +4.3% over one month, +36.8% over six months, +526.5% over one year.
Short interest was 37.0M shares at the Oct 15 settlement, up 4.6% from the prior report (14.5% of float, 6.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ERASErasca | $14.91 | +1.84% | +36.8% | — | — | — | $5.21B | |
| COGTCogent Biosciences | $31.49 | +1.38% | −12.2% | — | — | — | $5.46B | Compare |
| TVTXTravere Therapeutics | $52.42 | +6.09% | +17.1% | +36.2% | −23.3% | — | $4.94B | Compare |
| DNTHDianthus Therapeutics | $85.81 | +3.76% | −5.1% | +294.3% | −6598.6% | — | $4.80B | Compare |
| MANEVeradermics, Incorporated | $136.51 | +2.17% | +24.4% | — | — | — | $5.70B | Compare |
| PTCTPTC Therapeutics | $68.97 | +1.25% | +3.6% | +69.6% | −14.4% | — | $5.76B | Compare |
| DFTXDefinium Therapeutics | $32.70 | −2.13% | +39.6% | — | — | — | $4.39B | Compare |
| MIRMMirum Pharmaceuticals | $96.97 | +11.42% | −11.9% | +39.6% | −22.0% | — | $6.30B | Compare |
| LGNDLigand Pharmaceuticals | $316.13 | +0.83% | +35.9% | −31.8% | −36.2% | 122.9 | $6.32B | Compare |
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
